| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
IC50: 0.58 nM (melanocortin 4 receptor) IC50: 2.4 nM (melanocortin 5 receptor) IC50: 55 nM (melanocortin 3 receptor)[1]
MC4 (melanocortin 4) receptor. PG-931 is a potent and selective agonist at this receptor. |
|---|---|
| ln Vitro |
PG-931 is a potent MC4 receptor agonist with an IC50 of 0.58 nM at the human MC4 receptor. It is more selective for MC4 compared to hMC3R (IC50 = 55 nM) and hMC5R (IC50 = 2.4 nM). The key structural features include a cyclic lactam bridge and specific amino acids crucial for receptor binding and selectivity.
|
| ln Vivo |
In Wistar rats suffering from hemorrhagic shock, PG-931 (intravenous injection; 13-108 nmol/kg; single dosage) improves survival and restores circulatory and respiratory functions in a dose-dependent manner[2].
In vivo, PG-931 has been shown to reverse haemorrhagic shock and prevent multiple organ damage. This effect is attributed to its potent agonist activity at the MC4 receptor, which plays a role in the regulation of cardiovascular function and the inflammatory response to shock. |
| Enzyme Assay |
In vitro receptor binding assays are performed to determine the affinity of PG-931 for MC4, MC3, and MC5 receptors. Radioligand binding studies using membrane preparations from cells expressing the receptors are conducted. The compound's ability to displace a specific radiolabeled ligand from each receptor is measured to calculate its IC50 values.
|
| Cell Assay |
In vitro cell-based assays are conducted using cells expressing recombinant MC4 receptors. The cells are treated with PG-931, and receptor activation is measured by assessing downstream signaling events such as cAMP accumulation. The potency of the compound at MC4 is determined from these functional assays.
|
| Animal Protocol |
Animal/Disease Models: Wistar rats[2]
Doses: 13-108 nmol/kg Route of Administration: intravenous (iv) injection; single dose Experimental Results: demonstrated an anti-shock effect occurred at nanomolar doses. In vivo studies are conducted in animal models to evaluate the effects of PG-931 on haemorrhagic shock and organ damage. The compound is administered via various routes, and its effects on hemodynamic parameters, inflammatory markers, and organ function are assessed. |
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data are publicly available for PG-931. As a peptide, its pharmacokinetic properties would be characterized by limited oral bioavailability and rapid clearance. Its ADME properties would be studied in preclinical models to guide in vivo experiments.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are publicly available for PG-931. As a peptide agonist, its toxicity profile is expected to be related to its mechanism of action. Standard safety assessments would be required for any therapeutic development.
|
| References |
|
| Additional Infomation |
PG-931 is a potent and selective MC4 receptor agonist that has been shown to reverse haemorrhagic shock and prevent multiple organ damage in vivo. It is an analog of SHU 9119 and shares structural similarities with α-MSH. The compound is not approved for human therapeutic use and is strictly for research purposes.
|
| Molecular Formula |
C59H85N15O11
|
|---|---|
| Molecular Weight |
1180.40011286736
|
| Exact Mass |
1179.655
|
| CAS # |
667430-81-1
|
| Related CAS # |
PG-931 TFA
|
| PubChem CID |
90489007
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.3
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
85
|
| Complexity |
2380
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C([C@@H]1NC([C@H](NC([C@H](NC([C@]2([H])CCCN2C(=O)[C@@]([H])(NC(=O)[C@@H](NC(=O)C)CCCC)CC(=O)NCCCC[C@@H](C(N2CCC[C@H]2C(=O)N[C@H](C(=O)N)C(C)C)=O)NC1=O)=O)CC1C=CC=CC=1)=O)CCCNC(N)=N)=O)C1=CNC2=CC=CC=C12
|
| InChi Key |
WOFDJLFPEWSAPJ-RVBGBMFGSA-N
|
| InChi Code |
InChI=1S/C59H85N15O11/c1-5-6-20-40(66-35(4)75)51(78)71-45-32-48(76)63-26-13-12-22-42(57(84)73-28-16-25-47(73)56(83)72-49(34(2)3)50(60)77)68-54(81)44(31-37-33-65-39-21-11-10-19-38(37)39)69-52(79)41(23-14-27-64-59(61)62)67-53(80)43(30-36-17-8-7-9-18-36)70-55(82)46-24-15-29-74(46)58(45)85/h7-11,17-19,21,33-34,40-47,49,65H,5-6,12-16,20,22-32H2,1-4H3,(H2,60,77)(H,63,76)(H,66,75)(H,67,80)(H,68,81)(H,69,79)(H,70,82)(H,71,78)(H,72,83)(H4,61,62,64)/t40?,41-,42-,43-,44-,45-,46-,47-,49-/m0/s1
|
| Chemical Name |
(2S)-1-[(3S,11S,14S,17S,20S,23S)-3-(2-acetamidohexanoylamino)-20-benzyl-17-[3-(diaminomethylideneamino)propyl]-14-(1H-indol-3-ylmethyl)-2,5,13,16,19,22-hexaoxo-1,6,12,15,18,21-hexazabicyclo[21.3.0]hexacosane-11-carbonyl]-N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]pyrrolidine-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 100 mg/mL (84.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8472 mL | 4.2359 mL | 8.4717 mL | |
| 5 mM | 0.1694 mL | 0.8472 mL | 1.6943 mL | |
| 10 mM | 0.0847 mL | 0.4236 mL | 0.8472 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
